Alios BioPharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
Clinical Trials
23
Active:1
Completed:15
Trial Phases
3 Phases
Phase 1:17
Phase 2:5
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
Phase 1
17 (73.9%)Phase 2
5 (21.7%)Not Applicable
1 (4.3%)A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT03439488
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇲🇩Republican Clinical Hospital, Chisnau, Moldova, Republic of
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03411421
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT03285620
- Locations
- 🇳🇿
Auckland Clinical Studies, Ltd., Auckland, New Zealand
A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- Alios Biopharma Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03253471
- Locations
- 🇧🇪
SGS Life Sciences, Antwerp, Belgium
A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects
Phase 2
Withdrawn
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Alios Biopharma Inc.
- Registration Number
- NCT03125213
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found